SCHEMBL1705856

SCHEMBL1705856

Cc1cccc(-c2oc(C)nc2C(=O)Cl)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 5/20 0.46
HCRTR2 O43614 5/20 0.46
RXRA P19793 2/20 0.45
RXRB P28702 2/20 0.45
RXRG P48443 2/20 0.45
FPR2 P25090 5/20 0.43
PIN1 Q13526 1/20 0.43
NR4A2 P43354 1/20 0.42
IP6K1 Q92551 1/20 0.41
IP6K3 Q96PC2 1/20 0.41
IP6K2 Q9UHH9 1/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
GAA P10253 1/20 0.41
HTT P42858 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MAOB P27338 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
KMO O15229 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1167379 0.87 PIN1 (0.54) HCRTR1HCRTR2RXRARXRBRXRG
SCHEMBL9900638 0.85 RXRA (0.45) HCRTR1HCRTR2RXRARXRBRXRG
SCHEMBL4738316 0.81 TARBP2 (0.48) RXRARXRBRXRGFPR2NR4A2
SCHEMBL7948113 0.76 RAB9A (0.47) RXRARXRBRXRGNR4A2KDM4E
SCHEMBL15306135 0.76 FPR2 (0.44) HCRTR1HCRTR2RXRARXRBRXRG
SCHEMBL1166739 0.75 PIN1 (0.56) RXRARXRBRXRGFPR2PIN1
SCHEMBL18084238 0.75 FPR2 (0.45) HCRTR1HCRTR2RXRARXRBRXRG
SCHEMBL1166652 0.75 DUSP3 (0.46) RXRARXRBRXRGPIN1IP6K1
SCHEMBL15189705 0.74 RXRA (0.46) HCRTR1HCRTR2RXRARXRBRXRG
SCHEMBL9955506 0.73 RAB9A (0.41) RXRARXRBRXRGNR4A2IP6K1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8674111-B2 Oxazole and thiazole derivatives as ALX receptor agonists ACTELION PHARMACEUTICALS LTD. (CH) 2014-03-18 US disclosed
EP-2440536-B1 Oxazole and thiazole derivatives as ALX receptor agonists ACTELION PHARMACEUTICALS LTD (CH) 2013-11-06 EP disclosed
US-20120115916-A1 OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2012-05-10 US disclosed
EP-2440536-A1 OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS Actelion Pharmaceuticals Ltd. (CH) 2012-04-18 EP disclosed
WO-2010143158-A1 OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2010-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115916-A1 OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS P2RX1, GLP1R, P2RX7 HCRTR1 106/4885HCRTR2 69/4885RXRA 249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.